HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on IN8bio (NASDAQ:INAB) and maintained a $14 price target.

April 10, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on IN8bio and maintained a $14 price target.
The reiteration of a Buy rating and maintenance of a $14 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for IN8bio. This endorsement likely reflects confidence in the company's future performance and growth prospects, which could positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100